In the BioHarmony Drug Report Database
Ertugliflozin
Steglatro (ertugliflozin) is a small molecule pharmaceutical. Ertugliflozin was first approved as Steglatro on 2017-12-19. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2. In addition, it is known to target sodium/glucose cotransporter 1. Steglujan’s patent is valid until 2030-07-13 (FDA).
Trade Name
|
Steglatro |
|---|---|
Common Name
|
ertugliflozin |
ChEMBL ID
|
CHEMBL1770248 |
Indication
|
type 2 diabetes mellitus |
Drug Class
|
Phlorozin derivatives, phenolic glycosides |
Image (chem structure or protein)